Molecular Cancer Research最新文献

筛选
英文 中文
Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer. 确定晚期前列腺癌中雄激素受体变体合成的剪接因子要求。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-12-03 DOI: 10.1158/1541-7786.MCR-23-0958
Laura Walker, Ruaridh Duncan, Beth Adamson, Hannah Kendall, Nicholas Brittain, Sara Luzzi, Dominic Jones, Lewis Chaytor, Samantha Peel, Claire Crafter, Daniel J O'Neill, Luke Gaughan
{"title":"Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.","authors":"Laura Walker, Ruaridh Duncan, Beth Adamson, Hannah Kendall, Nicholas Brittain, Sara Luzzi, Dominic Jones, Lewis Chaytor, Samantha Peel, Claire Crafter, Daniel J O'Neill, Luke Gaughan","doi":"10.1158/1541-7786.MCR-23-0958","DOIUrl":"10.1158/1541-7786.MCR-23-0958","url":null,"abstract":"<p><p>Resistance to androgen receptor (AR)-targeted therapies represents a major challenge in prostate cancer. A key mechanism of treatment resistance in patients who progress to castration-resistant prostate cancer (CRPC) is the generation of alternatively spliced AR variants (AR-V). Unlike full-length AR isoforms, AR-Vs are constitutively active and refractory to current receptor-targeting agents and hence drive tumor progression. Identifying regulators of AR-V synthesis may therefore provide new therapeutic opportunities in combination with conventional AR-targeting agents. Our understanding of AR transcript splicing, and the factors that control the synthesis of AR-Vs, remains limited. Although candidate-based approaches have identified a small number of AR-V splicing regulators, an unbiased analysis of splicing factors important for AR-V generation is required to fill an important knowledge gap and furnish the field with novel and tractable targets for prostate cancer treatment. To that end, we conducted a bespoke CRISPR screen to profile splicing factor requirements for AR-V synthesis. MFAP1 and CWC22 were shown to be required for the generation of AR-V mRNA transcripts, and their depletion resulted in reduced AR-V protein abundance and cell proliferation in several CRPC models. Global transcriptomic analysis of MFAP1-depleted cells revealed both AR-dependent and -independent transcriptional impacts, including genes associated with DNA damage response. As such, MFAP1 downregulation sensitized prostate cancer cells to ionizing radiation, suggesting that therapeutically targeting AR-V splicing could provide novel cellular vulnerabilities which can be exploited in CRPC. Implications: We have utilized a CRISPR screening approach to identify key regulators of pathogenic AR splicing in prostate cancer.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":"1128-1142"},"PeriodicalIF":4.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation. TEAD2 通过 TAK1 转录激活促进肝细胞癌发展和索拉非尼抗性
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-12-03 DOI: 10.1158/1541-7786.MCR-24-0060
Yahui Zhang, Yidan Ren, Guoying Dong, Qinlian Jiao, Nan Guo, Ping Gao, Ya Li, Yunshan Wang, Wei Zhao
{"title":"TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation.","authors":"Yahui Zhang, Yidan Ren, Guoying Dong, Qinlian Jiao, Nan Guo, Ping Gao, Ya Li, Yunshan Wang, Wei Zhao","doi":"10.1158/1541-7786.MCR-24-0060","DOIUrl":"10.1158/1541-7786.MCR-24-0060","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, yet the effectiveness of treatment for patients with HCC is significantly hindered by the development of drug resistance to sorafenib. Through the application of accessibility sequencing to examine drug-resistant HCC tissues, we identified substantial alterations in chromatin accessibility in sorafenib-resistant patient-derived xenograft models. Employing multiomics data integration analysis, we confirmed that the key transcription factor TEAD2, which plays an important role in the Hippo signaling pathway, is a key factor in regulating sorafenib resistance in HCC. Functional assays illustrated that TEAD2 plays a role in promoting HCC progression and enhancing resistance to sorafenib. Mechanistically, we demonstrated that TEAD2 binds to the TAK1 promoter to modulate its expression. Furthermore, we established the involvement of TAK1 in mediating TEAD2-induced sorafenib resistance in HCC, a finding supported by the effectiveness of TAK1 inhibitors. Our research highlights that targeting the TEAD2-TAK1 axis can effectively mitigate drug resistance in patients with HCC receiving sorafenib treatment, offering a novel approach for enhancing the treatment outcomes and prognosis of individuals with HCC. Implications: Targeting the TEAD2-TAK1 axis presents a promising therapeutic strategy to overcome sorafenib resistance in HCC, potentially improving treatment outcomes and prognosis for patients.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":"1102-1116"},"PeriodicalIF":4.1,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-derived EBV-miR-BART2-5p promotes nasopharyngeal carcinoma metastasis by inducing pre-metastatic endothelial cell pyroptosis. 肿瘤衍生的EBV-miR-BART2-5p通过诱导转移前内皮细胞热解促进鼻咽癌转移。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-15 DOI: 10.1158/1541-7786.MCR-24-0165
Xingrui Chen, Qiqi Li, Xiaoyan Fu, Jike Li, Jun Deng, Qianbing Zhang, Mengying Qiu, Xiaoming Lyu, Linbo Cai, Hainan Li, Xin Li, Kaitai Yao, Jiahong Wang, Zhongxi Huang, Liang Chen, Jiangyu Zhang, Dengke Li
{"title":"Tumor-derived EBV-miR-BART2-5p promotes nasopharyngeal carcinoma metastasis by inducing pre-metastatic endothelial cell pyroptosis.","authors":"Xingrui Chen, Qiqi Li, Xiaoyan Fu, Jike Li, Jun Deng, Qianbing Zhang, Mengying Qiu, Xiaoming Lyu, Linbo Cai, Hainan Li, Xin Li, Kaitai Yao, Jiahong Wang, Zhongxi Huang, Liang Chen, Jiangyu Zhang, Dengke Li","doi":"10.1158/1541-7786.MCR-24-0165","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0165","url":null,"abstract":"<p><p>Extravasation is a key step in tumor metastasis. Epstein‒Barr virus (EBV) plays a crucial role in nasopharyngeal carcinoma (NPC) metastasis. However, the functions and molecular mechanisms of EBV during tumor cell extravasation remains unclear. Here, we showed that the expression of pyroptosis-associated proteins is greater in the endothelial cells of metastatic NPC tissues than in those of nontumor tissues Exosomes derived from NPC cells promoted endothelial cell pyroptosis, vascular permeability, and tumor cell extravasation. Moreover, we found that BART2-5p is abundant in serum exosomes from NPC patients with metastasis and NPC cells, and that it regulates endothelial cell pyroptosis in pre-metastatic organs via MRE11A. Exosomes containing a BART2-5p inhibitor and AAV-MRE11A attenuated endothelial cell pyroptosis and tumor metastasis. Moreover, in the endothelial cells of metastatic tissues from NPC patients, the BART2-5p level was positively associated with pyroptosis-related protein expression. Collectively, our findings suggest that exosomal BART2-5p is involved in pre-metastatic niche formation, identifying secreted BART2-5p as a potential therapeutic target for NPC metastasis. Implications: The finding that secreted BART2-5p is involved in pre-metastatic niche formation may aid the development of potential therapeutic target for NPC metastasis.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TIPE inhibits ferroptosis in colorectal cancer cells by regulating MGST1/ALOX5. TIPE 通过调控 MGST1/ALOX5 抑制结直肠癌细胞的铁突变。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-08 DOI: 10.1158/1541-7786.MCR-24-0433
Changxiu Yan, Shengnan Yu, Jing Zhang, Zhen Li, Zeyang Lin, Shiying Zhang, Haoyang Li, Zhijian Ye, Jiyi Huang, Yuhan Ye, Guohong Zhuang
{"title":"TIPE inhibits ferroptosis in colorectal cancer cells by regulating MGST1/ALOX5.","authors":"Changxiu Yan, Shengnan Yu, Jing Zhang, Zhen Li, Zeyang Lin, Shiying Zhang, Haoyang Li, Zhijian Ye, Jiyi Huang, Yuhan Ye, Guohong Zhuang","doi":"10.1158/1541-7786.MCR-24-0433","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0433","url":null,"abstract":"<p><p>TIPE is a protein highly expressed in various cancers that promotes ferroptosis in colorectal cancer (CRC) cells. Ferroptosis is a non-apoptotic cell death caused by lipid peroxidation, and MGST1 is a critical enzyme that resists lipid peroxidation. This study explored how TIPE regulates MGST1 expression to inhibit ferroptosis and promote CRC proliferation. TIPE was highly expressed in CRC tissues and positively correlated with the proliferation of human CRC cells. We measured levels of reactive oxygen species (ROS) and lipid-ROS in CRC cells with differential expression of TIPE and detected ferroptosis using transmission electron microscopy. Bioinformatics analysis revealed a positive correlation of expression patterns between TIPE and MGST1 in CRC. TIPE regulated the expression of MGST1 by activating the phosphorylation of ERK1/2. Co-immunoprecipitation revealed binding between MGST1 and ALOX5. This binding inhibited the phosphorylation of ALOX5, inhibiting ferroptosis and promoting the proliferation of CRC cells. A tumor formation experiment in nude mice supported our findings that TIPE regulates the proliferation of CRC by regulating ferroptosis. Implications: TIPE inhibits CRC ferroptosis via an MGST1-ALOX5 interaction to promote CRC proliferation. These findings suggest future CRC treatment strategies.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ASAP1 and ARF1 regulate myogenic differentiation in rhabdomyosarcoma by modulating TAZ activity. ASAP1和ARF1通过调节TAZ的活性调控横纹肌肉瘤的成肌分化。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-04 DOI: 10.1158/1541-7786.MCR-24-0490
Katie E Hebron, Olivia L Perkins, Angela Kim, Xiaoying Jian, Sofia A Girald-Berlingeri, Haiyan Lei, Jack F Shern, Elizabeth A Conner, Paul A Randazzo, Marielle E Yohe
{"title":"ASAP1 and ARF1 regulate myogenic differentiation in rhabdomyosarcoma by modulating TAZ activity.","authors":"Katie E Hebron, Olivia L Perkins, Angela Kim, Xiaoying Jian, Sofia A Girald-Berlingeri, Haiyan Lei, Jack F Shern, Elizabeth A Conner, Paul A Randazzo, Marielle E Yohe","doi":"10.1158/1541-7786.MCR-24-0490","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0490","url":null,"abstract":"<p><p>Despite aggressive, multimodal therapies, the prognosis of patients with refractory or recurrent rhabdomyosarcoma (RMS) has not improved in four decades. Because RMS resembles skeletal muscle precursor cells, differentiation-inducing therapy has been proposed for patients with advanced disease. In RAS-mutant PAX fusion-negative RMS (FN-FMS) preclinical models, MEK1/2 inhibition (MEKi) induces differentiation, slows tumor growth, and extends survival. However, the response is short-lived. A better understanding of the molecular mechanisms regulating FN-RMS differentiation could improve differentiation therapy. Here, we identified a role in FN-RMS differentiation for ASAP1, an ARF GTPase-activating protein (ARF GAP) with both pro-invasive and tumor suppressor functions. We found that ASAP1 knockdown inhibited differentiation in FN-RMS cells. Interestingly, knockdown of the GTPases ARF1 or ARF5, targets of ASAP1 GAP activity, also blocked differentiation of FN-RMS. We discovered that loss of ARF pathway components blocked myogenic transcription factor expression. Therefore, we examined the effects on transcriptional regulators. MEKi led to the phosphorylation and inactivation of WWTR1 (TAZ), a homolog of the pro-proliferative transcriptional co-activator YAP1 regulated by the Hippo pathway. However, loss of ASAP1 or ARF1 blocked this inactivation, which inhibits MEKi-induced differentiation. Finally, MEKi-induced differentiation was rescued by dual knockdown of ASAP1 and WWTR1. This study shows that ASAP1 and ARF1 are necessary for myogenic differentiation, providing a deeper understanding of differentiation in FN-RMS and illuminating an opportunity to advance differentiation therapy. Implications: ASAP1 and ARF1 regulate MEKi-induced differentiation of FN-RMS cells by modulating WWTR1 (TAZ) activity, supporting YAP1/TAZ inhibition as a FN-RMS differentiation therapy strategy.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: miRNA-302b Suppresses Human Hepatocellular Carcinoma by Targeting AKT2. 撤稿:miRNA-302b 通过靶向 AKT2 抑制人类肝细胞癌。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-01 DOI: 10.1158/1541-7786.MCR-24-0723
Lumin Wang, Jiayi Yao, Xiaogang Zhang, Bo Guo, Xiaofeng Le, Mark Cubberly, Zongfang Li, Kejun Nan, Tusheng Song, Chen Huang
{"title":"Retraction: miRNA-302b Suppresses Human Hepatocellular Carcinoma by Targeting AKT2.","authors":"Lumin Wang, Jiayi Yao, Xiaogang Zhang, Bo Guo, Xiaofeng Le, Mark Cubberly, Zongfang Li, Kejun Nan, Tusheng Song, Chen Huang","doi":"10.1158/1541-7786.MCR-24-0723","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0723","url":null,"abstract":"","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":"22 11","pages":"1067"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. 撤回:Rac1 通路在胃腺癌上皮细胞向间质转化和癌干样细胞表型中的作用
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-01 DOI: 10.1158/1541-7786.MCR-24-0857
Changhwan Yoon, Seo-Jeong Cho, Kevin K Chang, Do Joong Park, Sandra W Ryeom, Sam S Yoon
{"title":"Retraction: Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma.","authors":"Changhwan Yoon, Seo-Jeong Cho, Kevin K Chang, Do Joong Park, Sandra W Ryeom, Sam S Yoon","doi":"10.1158/1541-7786.MCR-24-0857","DOIUrl":"10.1158/1541-7786.MCR-24-0857","url":null,"abstract":"","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":"22 11","pages":"1068"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis. 撤回:表达CagA的幽门螺杆菌诱导CDX1表达促进胃肿瘤发生
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-01 DOI: 10.1158/1541-7786.MCR-24-0859
Sang Il Choi, Changhwan Yoon, Mi Ree Park, DaHyung Lee, Myeong-Cherl Kook, Jian-Xian Lin, Jun Hyuk Kang, Hassan Ashktorab, Duane T Smoot, Sam S Yoon, Soo-Jeong Cho
{"title":"Retraction: CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis.","authors":"Sang Il Choi, Changhwan Yoon, Mi Ree Park, DaHyung Lee, Myeong-Cherl Kook, Jian-Xian Lin, Jun Hyuk Kang, Hassan Ashktorab, Duane T Smoot, Sam S Yoon, Soo-Jeong Cho","doi":"10.1158/1541-7786.MCR-24-0859","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0859","url":null,"abstract":"","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":"22 11","pages":"1065"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function. GRAIL1 通过独立于泛素连接酶的伴侣调节功能稳定折叠错误的突变 p53。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-01 DOI: 10.1158/1541-7786.MCR-24-0361
Paramita Ray, Sangeeta Jaiswal, Daysha Ferrer-Torres, Zhuwen Wang, Derek Nancarrow, Meghan Curtin, May San Martinho, Shannon M Lacy, Srimathi Kasturirangan, Dafydd Thomas, Jason R Spence, Matthias C Truttmann, Kiran H Lagisetty, Theodore S Lawrence, Thomas D Wang, David G Beer, Dipankar Ray
{"title":"GRAIL1 Stabilizes Misfolded Mutant p53 through a Ubiquitin Ligase-Independent, Chaperone Regulatory Function.","authors":"Paramita Ray, Sangeeta Jaiswal, Daysha Ferrer-Torres, Zhuwen Wang, Derek Nancarrow, Meghan Curtin, May San Martinho, Shannon M Lacy, Srimathi Kasturirangan, Dafydd Thomas, Jason R Spence, Matthias C Truttmann, Kiran H Lagisetty, Theodore S Lawrence, Thomas D Wang, David G Beer, Dipankar Ray","doi":"10.1158/1541-7786.MCR-24-0361","DOIUrl":"10.1158/1541-7786.MCR-24-0361","url":null,"abstract":"<p><p>Frequent (>70%) TP53 mutations often promote its protein stabilization, driving esophageal adenocarcinoma (EAC) development linked to poor survival and therapy resistance. We previously reported that during Barrett's esophagus progression to EAC, an isoform switch occurs in the E3 ubiquitin ligase RNF128 (aka GRAIL-gene related to anergy in lymphocytes), enriching isoform 1 (hereby GRAIL1) and stabilizing the mutant p53 protein. Consequently, GRAIL1 knockdown degrades mutant p53. But, how GRAIL1 stabilizes the mutant p53 protein remains unclear. In search for a mechanism, here, we performed biochemical and cell biology studies to identify that GRAIL has a binding domain (315-PMCKCDILKA-325) for heat shock protein 40/DNAJ. This interaction can influence DNAJ chaperone activity to modulate misfolded mutant p53 stability. As predicted, either the overexpression of a GRAIL fragment (Frag-J) encompassing the DNAJ binding domain or a cell-permeable peptide (Pep-J) encoding the above 10 amino acids can bind and inhibit DNAJ-Hsp70 co-chaperone activity, thus degrading misfolded mutant p53. Consequently, either Frag-J or Pep-J can reduce the survival of mutant p53 containing dysplastic Barrett's esophagus and EAC cells and inhibit the growth of patient-derived organoids of dysplastic Barrett's esophagus in 3D cultures. The misfolded mutant p53 targeting and growth inhibitory effects of Pep-J are comparable with simvastatin, a cholesterol-lowering drug that can degrade misfolded mutant p53 also via inhibiting DNAJA1, although by a distinct mechanism. Implications: We identified a novel ubiquitin ligase-independent, chaperone-regulating domain in GRAIL and further synthesized a first-in-class novel misfolded mutant p53 degrading peptide having future translational potential.</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":"996-1010"},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. 致癌 KRAS 突变对结直肠癌细胞的蠕动产生独特的机制传导反应。
IF 4.1 2区 医学
Molecular Cancer Research Pub Date : 2024-11-01 DOI: 10.1158/1541-7786.MCR-24-0624
Abigail J Clevenger, Claudia A Collier, John Paul M Gorley, Sarah Colijn, Maygan K McFarlin, Spencer C Solberg, E Scott Kopetz, Amber N Stratman, Shreya A Raghavan
{"title":"Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells.","authors":"Abigail J Clevenger, Claudia A Collier, John Paul M Gorley, Sarah Colijn, Maygan K McFarlin, Spencer C Solberg, E Scott Kopetz, Amber N Stratman, Shreya A Raghavan","doi":"10.1158/1541-7786.MCR-24-0624","DOIUrl":"https://doi.org/10.1158/1541-7786.MCR-24-0624","url":null,"abstract":"<p><p>Colorectal cancer (CRC) tumors start as polyps on the inner lining of the colorectum, where they are exposed to the mechanics of peristalsis. Our previous work leveraged a custom-built peristalsis bioreactor to demonstrate that colonic peristalsis led to cancer stem cell enrichment in CRC cells. However, this malignant mechanotransductive response was confined to select CRC lines that harbored an oncogenic mutation in the KRAS gene. Here, we explored the involvement of activating KRAS mutations on peristalsis-associated mechanotransduction in CRC. Peristalsis enriched cancer stem cell marker LGR5 in KRAS mutant lines, in a Wnt-ligand-independent manner. Conversely, LGR5 enrichment in wild type KRAS lines exposed to peristalsis were minimal. LGR5 enrichment downstream of peristalsis translated to increased tumorigenicity in vivo. Differences in mechanotransduction was apparent via unbiased gene set enrichment analysis, where many unique pathways were enriched in wild type vs. mutant lines. Peristalsis also triggered β-catenin nuclear localization independent of Wnt-ligands, particularly in KRAS mutant lines. The involvement of KRAS was validated via gain and loss of function strategies. Peristalsis induced β-catenin activation and LGR5 enrichment depended on the activation of the MEK/ERK cascade. Taken together, our results demonstrated that oncogenic KRAS mutations conferred a unique peristalsis-associated mechanotransduction response to colorectal cancer cells, resulting in cancer stem cell enrichment and increased tumorigenicity. These mechanosensory connections can be leveraged in improving the sensitivity of emerging therapies that target oncogenic KRAS. Implications: Oncogenic KRAS empowers colorectal cancer cells to harness the mechanics of colonic peristalsis for malignant gain, independent of other cooperating signals. .</p>","PeriodicalId":19095,"journal":{"name":"Molecular Cancer Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信